Accretion Pharmaceuticals, a Gujarat-based pharma manufacturer, concluded its SME IPO with a strong subscription of 7.31 times. The IPO, priced at Rs 96-101 per share, aims to utilize proceeds for capital expenditures and facility upgrades. Despite robust financial growth and international presence, the grey market premium remained flat, indicating market caution ahead of its NSE SME platform listing.
Geopolitics, crude risk and the IT conundrum: Sridhar Sivaram on why investors may need to stay selective
Geopolitical tensions in West Asia are creating market uncertainty, impacting energy supplies and capital flows. While Indian equities have shown resilience, prolonged conflict could significantly